PSTX - Poseida Therapeutics GAAP EPS of -$0.35 revenue of $9.35M
2023-11-10 10:48:08 ET
More on Poseida Therapeutics
- Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade)
- Poseida Therapeutics' Financial And Clinical Milestones Signal Upgrade To 'Strong Buy'
- Poseida Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Poseida Therapeutics appoints Kristin Yarema as CEO
- Seeking Alpha’s Quant Rating on Poseida Therapeutics
For further details see:
Poseida Therapeutics GAAP EPS of -$0.35, revenue of $9.35M